Lightspeed's magic number

Forty Seven Inc.'s combination of novel mechanism, advanced stage of development and management team convinced Lightspeed Venture Partners to make its first-ever therapeutics investment.

On Feb. 24, the newco raised $75 million in a series A round co-led by Lightspeed and Sutter Hill Ventures, with participation from Clarus Ventures and GV (formerly Google Ventures). Alongside the financing, Forty Seven received exclusive, worldwide rights from Stanford University to a pipeline of immuno-oncology molecules. ...